Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Tamura A"'
Autor:
Yoshinobu Saito, Masahiko Kusumoto, Yuichiro Ohe, Masafumi Sata, Kei Sakamoto, Terufumi Kato, Toshimitsu Tokimoto, Reiko Tamura, Tomohisa Baba, Akihiko Gemma, Masatoshi Sugeno, Ou Yamaguchi, Wataru Shimizu, Masahiro Endo, Fumikazu Sakai
Publikováno v:
Japanese Journal of Clinical Oncology
Objective Adverse drug reactions (ADRs) during real-world osimertinib use were investigated in Japan. Methods Patients with epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer treated with second-line or later oral osime
Autor:
Tetsuya Abe, Tetsu Shinkai, Akira Yokoyama, Shigeki Mitsuoka, Nagahiro Saijo, Masahiko Ando, Hiroshi Katayama, Kazuhiko Nakagawa, Kenich Nakamura, Hiroaki Okamoto, Tomohide Tamura, Yuichro Ohe, Hiroshige Yoshioka, Haruhiko Fukuda, Koji Takeda, Junki Mizusawa, Nobuyuki Yamamoto, Shinichiro Nakamura
Publikováno v:
Japanese journal of clinical oncology. 51(5)
Objective Patients’ actual age and performance status do not always accurately identify the ‘fit elderly’ for chemotherapy. This study aimed to determine whether four geriatric assessment tools could predict prognosis. Methods This study were a
Autor:
Tomohide Tamura, Naoyuki Nogami, Koichi Minato, Hiroshi Tanaka, Miyako Satouchi, Makoto Maemondo, Nobumichi Yada, Hidehito Horinouchi, Tomonori Hirashima, Hiroshi Sakai, M. Nishio, Koji Takeda, Hiroshi Isobe, Toshiaki Takahashi, Shinji Atagi, Nobuyuki Katakami, Koichi Goto, Mitsuhiro Takenoyama, Kazuhiko Nakagawa, Toyoaki Hida, Hideo Saka
Publikováno v:
Japanese Journal of Clinical Oncology
Background Two phase II studies in Japan examined the efficacy and safety of nivolumab, a programmed cell death 1 receptor inhibitor, in patients with advanced squamous and non-squamous non-small cell lung cancer (ONO-4538-05 and ONO-4538-06). We exa
Autor:
Hiroko, Tsukada, Akira, Yokoyama, Koichi, Goto, Tetsu, Shinkai, Masao, Harada, Masahiko, Ando, Taro, Shibata, Yuichiro, Ohe, Tomohide, Tamura, Nagahiro, Saijo, S, Yokota
Publikováno v:
Japanese Journal of Clinical Oncology. 45:88-95
OBJECTIVE Prospective trials specifically designed for elderly patients with advanced non-small-cell lung cancer demonstrating the benefit of platinum-based therapies are still lacking. This trial was designed to clarify whether the addition of cispl
Autor:
Koji Tsuta, Noboru Yamamoto, Satoru Kitazono, Tomohide Tamura, Taisuke Mori, Shintaro Kanda, Yutaka Fujiwara, Shigehiro Yagishita, Hidehito Horinouchi, Hiroshi Nokihara, Minako Sumi, Takashi Yorozu, Hidenori Mizugaki
Publikováno v:
Japanese Journal of Clinical Oncology. 44:191-194
A 53-year-old female patient was admitted with pain and a progressively enlarging mass in the right upper chest. Chest computed tomography revealed a mass lesion in the region of the right upper ribs. Ten years prior to this admission, the patient ha
Autor:
Shinji Nakamichi, Tomoko Taniyama, Ikuo Sekine, Noboru Yamamoto, Hidehito Horinouchi, Hiroshi Nokihara, Kaoru Kubota, Tomohide Tamura, Shintaro Kanda, Hiroshi Wakui, Hidetoshi Itani
Publikováno v:
Japanese Journal of Clinical Oncology. 43:1105-1109
Objective We previously reported that 22% of lung cancer patients experienced a Grade 2 or 3 elevation in creatinine after chemotherapy containing cisplatin. We conducted a Phase II trial to evaluate the safety and efficacy of short hydration. Method
Autor:
Hiroshi Yamamoto, Hiroshi Nokihara, Reiko Ando Makihara, Ikuo Sekine, Yuichiro Ohe, Noboru Yamamoto, Tomohide Tamura, Nobuaki Yokote, Yoshinori Makino
Publikováno v:
Japanese Journal of Clinical Oncology. 42:1187-1191
Background: Severe hematological toxicity has been frequently observed during amrubicin monotherapy for patients with lung cancer despite the favorable anti-tumor response. The purpose of this retrospective study was to identify pretreatment factors
Autor:
Daisuke Tamura, Motoko Tachihara, Hiroshi Otera, Yasuhiro Funada, Yoshihiro Nishimura, Yumiko Ishikawa, Kazuyuki Kobayashi, Suya Hori
Publikováno v:
Japanese Journal of Clinical Oncology. 44:762-764
We report the case of a 70-year-old Japanese male diagnosed with advanced lung adenocarcinoma harboring the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene. As soon as crizotinib was administered, tumor shrank
Publikováno v:
Japanese Journal of Clinical Oncology. 40:732-738
Temsirolimus (CCI-779) is a novel inhibitor of the mammalian target of rapamycin. This Phase 1 study was aimed at investigating the maximum-tolerated dose, toxicity, pharmacokinetics and antitumor activity in Japanese patients with advanced solid tum
Autor:
Yuichiro Ohe, Hideo Kunitoh, Noboru Yamamoto, Tetsuro Kodama, Nagahiro Saijo, Yasuhito Fujisaka, Hiroshi Nokihara, Ikuo Sekine, Atsushi Horiike, Tomohide Tamura
Publikováno v:
Japanese Journal of Clinical Oncology. 36:477-482
Background To assess the pharmacokinetic profile and time-course of trough concentrations and hemoglobin levels associated with subcutaneous weekly administration of epoetin beta in lung cancer patients with chemotherapy-induced anemia. Methods Epoet